Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Cabenuva kit patents litigation?Diphenhydramine hydrochloride api?The bristol myers squibb pfizer alliance is pleased with the decision by the u's court of appeals for the federal circuit upholding the eliquis patents?Praluent alirocumab patent?Alirocumab patent expiry china?
See the DrugPatentWatch profile for Dihydroergotamine
Dihydroergotamine (DHE) belongs to the ergot alkaloid drug class. These medicines are derived from ergot (a fungus) and act on serotonin and dopamine receptors, which can affect blood vessel tone and related migraine and vascular symptoms.
Dihydroergotamine is most commonly used in migraine therapy. Because it comes from the ergot alkaloids, it is generally discussed with other “ergot” migraine medicines (often in the same therapeutic category of antimigraine agents that act on vascular and neurologic pathways).
Dihydroergotamine is an ergot alkaloid, not a triptan. Triptans (such as sumatriptan) are a different class of antimigraine drugs. DHE is related to ergotamine, which is another ergot alkaloid used for migraine.
Yes. Ergot alkaloids like dihydroergotamine are associated with vasoconstrictive activity, which is part of why they have activity in migraine and certain other conditions involving abnormal vascular responses.
No external sources were provided in the prompt, so I did not add citations.
Other Questions About Dihydroergotamine :